Fractional  ||| S:0 E:11 ||| JJ
flow  ||| S:11 E:16 ||| NN
reserve  ||| S:16 E:24 ||| NN
evaluation  ||| S:24 E:35 ||| NN
and  ||| S:35 E:39 ||| CC
chronic  ||| S:39 E:47 ||| JJ
kidney  ||| S:47 E:54 ||| NN
disease ||| S:54 E:61 ||| NN
:  ||| S:61 E:63 ||| :
Analysis  ||| S:63 E:72 ||| NNP
from  ||| S:72 E:77 ||| IN
a  ||| S:77 E:79 ||| DT
multicenter  ||| S:79 E:91 ||| JJ
Italian  ||| S:91 E:99 ||| JJ
registry  ||| S:99 E:108 ||| NNS
( ||| S:108 E:109 ||| -LRB-
the  ||| S:109 E:113 ||| DT
FREAK  ||| S:113 E:119 ||| NNP
study ||| S:119 E:124 ||| NN
)  ||| S:124 E:126 ||| -RRB-
To  ||| S:126 E:129 ||| TO
establish  ||| S:129 E:139 ||| VB
if  ||| S:139 E:142 ||| IN
the  ||| S:142 E:146 ||| DT
presence  ||| S:146 E:155 ||| NN
of  ||| S:155 E:158 ||| IN
chronic  ||| S:158 E:166 ||| JJ
kidney  ||| S:166 E:173 ||| NN
disease  ||| S:173 E:181 ||| NN
( ||| S:181 E:182 ||| -LRB-
CKD ||| S:182 E:185 ||| NNP
)  ||| S:185 E:187 ||| -RRB-
influences  ||| S:187 E:198 ||| VBZ
fractional  ||| S:198 E:209 ||| JJ
flow  ||| S:209 E:214 ||| NN
reserve  ||| S:214 E:222 ||| NN
( ||| S:222 E:223 ||| -LRB-
FFR ||| S:223 E:226 ||| NNP
)  ||| S:226 E:228 ||| -RRB-
value  ||| S:228 E:234 ||| NN
in  ||| S:234 E:237 ||| IN
patients  ||| S:237 E:246 ||| NNS
with  ||| S:246 E:251 ||| IN
intermediate  ||| S:251 E:264 ||| JJ
coronary  ||| S:264 E:273 ||| JJ
stenosis ||| S:273 E:281 ||| NN
.  ||| S:281 E:283 ||| .
FFR-guided  ||| S:283 E:294 ||| JJ
coronary  ||| S:294 E:303 ||| JJ
revascularization  ||| S:303 E:321 ||| NN
reduces  ||| S:321 E:329 ||| VBZ
cardiac  ||| S:329 E:337 ||| JJ
adverse  ||| S:337 E:345 ||| JJ
events  ||| S:345 E:352 ||| NNS
in  ||| S:352 E:355 ||| IN
patients  ||| S:355 E:364 ||| NNS
with  ||| S:364 E:369 ||| IN
coronary  ||| S:369 E:378 ||| JJ
artery  ||| S:378 E:385 ||| NN
disease ||| S:385 E:392 ||| NN
.  ||| S:392 E:394 ||| .
CKD  ||| S:394 E:398 ||| NNP
impairs  ||| S:398 E:406 ||| NN
microcirculation  ||| S:406 E:423 ||| NNS
and  ||| S:423 E:427 ||| CC
increases  ||| S:427 E:437 ||| NNS
cardiovascular  ||| S:437 E:452 ||| JJ
risk ||| S:452 E:456 ||| NN
.  ||| S:456 E:458 ||| .
Whether  ||| S:458 E:466 ||| IN
CKD  ||| S:466 E:470 ||| NNP
presence  ||| S:470 E:479 ||| NN
may  ||| S:479 E:483 ||| MD
limit  ||| S:483 E:489 ||| VB
FFR  ||| S:489 E:493 ||| JJ
accuracy  ||| S:493 E:502 ||| NN
is  ||| S:502 E:505 ||| VBZ
unknown ||| S:505 E:512 ||| JJ
.  ||| S:512 E:514 ||| .
We  ||| S:514 E:517 ||| PRP
used  ||| S:517 E:522 ||| VBD
data  ||| S:522 E:527 ||| NNS
from  ||| S:527 E:532 ||| IN
a  ||| S:532 E:534 ||| DT
multicenter  ||| S:534 E:546 ||| FW
prospective  ||| S:546 E:558 ||| FW
registry  ||| S:558 E:567 ||| FW
enrolling  ||| S:567 E:577 ||| FW
1.004  ||| S:577 E:583 ||| FW
patients  ||| S:583 E:592 ||| FW
undergoing  ||| S:592 E:603 ||| FW
FFR  ||| S:603 E:607 ||| FW
evaluation  ||| S:607 E:618 ||| NN
for  ||| S:618 E:622 ||| IN
intermediate  ||| S:622 E:635 ||| JJ
stenosis ||| S:635 E:643 ||| NN
.  ||| S:643 E:645 ||| .
We  ||| S:645 E:648 ||| PRP
assessed  ||| S:648 E:657 ||| VBD
the  ||| S:657 E:661 ||| DT
relationship  ||| S:661 E:674 ||| NN
between  ||| S:674 E:682 ||| IN
clinical  ||| S:682 E:691 ||| JJ
and  ||| S:691 E:695 ||| CC
angiographic  ||| S:695 E:708 ||| JJ
variables  ||| S:708 E:718 ||| NNS
and  ||| S:718 E:722 ||| CC
FFR  ||| S:722 E:726 ||| NNP
measurement ||| S:726 E:737 ||| NN
.  ||| S:737 E:739 ||| .
CKD  ||| S:739 E:743 ||| NNP
was  ||| S:743 E:747 ||| VBD
defined  ||| S:747 E:755 ||| VBN
as  ||| S:755 E:758 ||| IN
CrCl  ||| S:758 E:763 ||| JJ
value  ||| S:763 E:769 ||| NN
≤45  ||| S:769 E:773 ||| FW
ml ||| S:773 E:775 ||| FW
/ ||| S:775 E:776 ||| FW
min ||| S:776 E:779 ||| FW
.  ||| S:779 E:781 ||| .
FFR  ||| S:781 E:785 ||| SYM
value  ||| S:785 E:791 ||| NN
was  ||| S:791 E:795 ||| VBD
considered  ||| S:795 E:806 ||| VBN
potentially  ||| S:806 E:818 ||| RB
flow-limiting ||| S:818 E:831 ||| JJ
,  ||| S:831 E:833 ||| ,
and  ||| S:833 E:837 ||| CC
therefore  ||| S:837 E:847 ||| RB
positive ||| S:847 E:855 ||| JJ
,  ||| S:855 E:857 ||| ,
if  ||| S:857 E:860 ||| IN
≤0.80 ||| S:860 E:865 ||| CD
.  ||| S:865 E:867 ||| .
The  ||| S:867 E:871 ||| DT
index  ||| S:871 E:877 ||| NN
of  ||| S:877 E:880 ||| IN
microcirculatory  ||| S:880 E:897 ||| JJ
resistance  ||| S:897 E:908 ||| NN
( ||| S:908 E:909 ||| -LRB-
IMR ||| S:909 E:912 ||| NNP
)  ||| S:912 E:914 ||| -RRB-
was  ||| S:914 E:918 ||| VBD
calculated  ||| S:918 E:929 ||| VBN
in  ||| S:929 E:932 ||| IN
20  ||| S:932 E:935 ||| CD
patients  ||| S:935 E:944 ||| NNS
stratified  ||| S:944 E:955 ||| VBP
according  ||| S:955 E:965 ||| VBG
CrCl  ||| S:965 E:970 ||| JJ
value  ||| S:970 E:976 ||| NN
( ||| S:976 E:977 ||| -LRB-
single-center  ||| S:977 E:991 ||| JJ
substudy ||| S:991 E:999 ||| NN
) ||| S:999 E:1000 ||| -RRB-
.  ||| S:1000 E:1002 ||| .
FFR  ||| S:1002 E:1006 ||| SYM
measurement  ||| S:1006 E:1018 ||| NN
was  ||| S:1018 E:1022 ||| VBD
positive  ||| S:1022 E:1031 ||| JJ
in  ||| S:1031 E:1034 ||| IN
395  ||| S:1034 E:1038 ||| CD
( ||| S:1038 E:1039 ||| -LRB-
39 ||| S:1039 E:1041 ||| CD
% ||| S:1041 E:1042 ||| NN
)  ||| S:1042 E:1044 ||| -RRB-
patients ||| S:1044 E:1052 ||| NNS
.  ||| S:1052 E:1054 ||| .
Overall ||| S:1054 E:1061 ||| RB
,  ||| S:1061 E:1063 ||| ,
131  ||| S:1063 E:1067 ||| CD
( ||| S:1067 E:1068 ||| -LRB-
13 ||| S:1068 E:1070 ||| CD
% ||| S:1070 E:1071 ||| NN
)  ||| S:1071 E:1073 ||| -RRB-
patients  ||| S:1073 E:1082 ||| NNS
had  ||| S:1082 E:1086 ||| VBD
CKD ||| S:1086 E:1089 ||| NNP
.  ||| S:1089 E:1091 ||| .
Patients  ||| S:1091 E:1100 ||| NNS
with  ||| S:1100 E:1105 ||| IN
CrCl  ||| S:1105 E:1110 ||| JJ
≤45  ||| S:1110 E:1114 ||| CD
ml ||| S:1114 E:1116 ||| CD
/ ||| S:1116 E:1117 ||| CD
min  ||| S:1117 E:1121 ||| NNS
showed  ||| S:1121 E:1128 ||| VBD
significantly  ||| S:1128 E:1142 ||| RB
higher  ||| S:1142 E:1149 ||| JJR
FFR  ||| S:1149 E:1153 ||| NNP
values  ||| S:1153 E:1160 ||| VBZ
as  ||| S:1160 E:1163 ||| RB
compared  ||| S:1163 E:1172 ||| VBN
to  ||| S:1172 E:1175 ||| TO
the  ||| S:1175 E:1179 ||| DT
others  ||| S:1179 E:1186 ||| NNS
( ||| S:1186 E:1187 ||| -LRB-
0.84  ||| S:1187 E:1192 ||| FW
±  ||| S:1192 E:1194 ||| FW
0.07  ||| S:1194 E:1199 ||| FW
vs.  ||| S:1199 E:1203 ||| FW
0.81  ||| S:1203 E:1208 ||| FW
±  ||| S:1208 E:1210 ||| FW
0.08 ||| S:1210 E:1214 ||| FW
,  ||| S:1214 E:1216 ||| ,
p    ||| S:1216 E:1218 ||| CD
< ||| S:1218 E:1219 ||| SYM
0.001 ||| S:1220 E:1225 ||| CD
) ||| S:1225 E:1226 ||| -RRB-
.  ||| S:1226 E:1228 ||| .
Positive  ||| S:1228 E:1237 ||| JJ
FFR  ||| S:1237 E:1241 ||| NNP
occurrence  ||| S:1241 E:1252 ||| NN
was  ||| S:1252 E:1256 ||| VBD
lower  ||| S:1256 E:1262 ||| JJR
in  ||| S:1262 E:1265 ||| IN
patients  ||| S:1265 E:1274 ||| NNS
with  ||| S:1274 E:1279 ||| IN
CrCl  ||| S:1279 E:1284 ||| FW
≤45  ||| S:1284 E:1288 ||| FW
ml ||| S:1288 E:1290 ||| FW
/ ||| S:1290 E:1291 ||| FW
min  ||| S:1291 E:1295 ||| FW
( ||| S:1295 E:1296 ||| -LRB-
27 ||| S:1296 E:1298 ||| CD
%  ||| S:1298 E:1300 ||| NN
vs.  ||| S:1300 E:1304 ||| IN
41 ||| S:1304 E:1306 ||| CD
% ||| S:1306 E:1307 ||| NN
,  ||| S:1307 E:1309 ||| ,
p    ||| S:1309 E:1311 ||| CD
< ||| S:1311 E:1312 ||| SYM
0.01 ||| S:1313 E:1317 ||| CD
) ||| S:1317 E:1318 ||| -RRB-
.  ||| S:1318 E:1320 ||| .
After  ||| S:1320 E:1326 ||| IN
multivariable  ||| S:1326 E:1340 ||| JJ
analysis ||| S:1340 E:1348 ||| NN
,  ||| S:1348 E:1350 ||| ,
diabetes  ||| S:1350 E:1359 ||| NN
( ||| S:1359 E:1360 ||| -LRB-
HR  ||| S:1360 E:1363 ||| NNP
1.07 ||| S:1363 E:1367 ||| CD
,  ||| S:1367 E:1369 ||| ,
95 ||| S:1369 E:1371 ||| CD
% ||| S:1371 E:1372 ||| NN
CI  ||| S:1372 E:1375 ||| NNP
1.008-1.13 ||| S:1375 E:1385 ||| NNP
,  ||| S:1385 E:1387 ||| ,
p  ||| S:1387 E:1389 ||| CD
=  ||| S:1389 E:1391 ||| CD
0.03 ||| S:1391 E:1395 ||| CD
) ||| S:1395 E:1396 ||| -RRB-
,  ||| S:1396 E:1398 ||| ,
left  ||| S:1398 E:1403 ||| VBD
anterior  ||| S:1403 E:1412 ||| JJ
descending  ||| S:1412 E:1423 ||| NNS
( ||| S:1423 E:1424 ||| -LRB-
HR  ||| S:1424 E:1427 ||| NNP
1.35 ||| S:1427 E:1431 ||| CD
,  ||| S:1431 E:1433 ||| ,
95 ||| S:1433 E:1435 ||| CD
% ||| S:1435 E:1436 ||| NN
CI  ||| S:1436 E:1439 ||| NNP
1.27-1.43 ||| S:1439 E:1448 ||| NNP
,  ||| S:1448 E:1450 ||| ,
p    ||| S:1450 E:1452 ||| CD
< ||| S:1452 E:1453 ||| SYM
0.001 ||| S:1454 E:1459 ||| CD
)  ||| S:1459 E:1461 ||| -RRB-
and  ||| S:1461 E:1465 ||| CC
CrCl  ||| S:1465 E:1470 ||| JJ
≤45  ||| S:1470 E:1474 ||| FW
ml ||| S:1474 E:1476 ||| FW
/ ||| S:1476 E:1477 ||| FW
min  ||| S:1477 E:1481 ||| FW
( ||| S:1481 E:1482 ||| -LRB-
HR  ||| S:1482 E:1485 ||| NNP
0.92 ||| S:1485 E:1489 ||| NNP
,  ||| S:1489 E:1491 ||| ,
95 ||| S:1491 E:1493 ||| CD
% ||| S:1493 E:1494 ||| NN
CI  ||| S:1494 E:1497 ||| NNP
0.87-0.97 ||| S:1497 E:1506 ||| NNP
,  ||| S:1506 E:1508 ||| ,
p  ||| S:1508 E:1510 ||| CD
=  ||| S:1510 E:1512 ||| CD
0.005 ||| S:1512 E:1517 ||| CD
)  ||| S:1517 E:1519 ||| -RRB-
emerged  ||| S:1519 E:1527 ||| VBD
as  ||| S:1527 E:1530 ||| IN
independent  ||| S:1530 E:1542 ||| JJ
predictors  ||| S:1542 E:1553 ||| NN
of  ||| S:1553 E:1556 ||| IN
FFR  ||| S:1556 E:1560 ||| NNP
measurement ||| S:1560 E:1571 ||| NN
.  ||| S:1571 E:1573 ||| .
Accordingly ||| S:1573 E:1584 ||| RB
,  ||| S:1584 E:1586 ||| ,
IMR  ||| S:1586 E:1590 ||| NNP
values  ||| S:1590 E:1597 ||| NNS
were  ||| S:1597 E:1602 ||| VBD
higher  ||| S:1602 E:1609 ||| JJR
in  ||| S:1609 E:1612 ||| IN
patients  ||| S:1612 E:1621 ||| NNS
with  ||| S:1621 E:1626 ||| IN
CrCl  ||| S:1626 E:1631 ||| FW
≤45  ||| S:1631 E:1635 ||| FW
ml ||| S:1635 E:1637 ||| FW
/ ||| S:1637 E:1638 ||| FW
min  ||| S:1638 E:1642 ||| FW
( ||| S:1642 E:1643 ||| -LRB-
32  ||| S:1643 E:1646 ||| CD
U  ||| S:1646 E:1648 ||| NNP
[ ||| S:1648 E:1649 ||| -LRB-
28245 ||| S:1649 E:1654 ||| LS
]  ||| S:1654 E:1656 ||| -RRB-
vs.  ||| S:1656 E:1660 ||| IN
16  ||| S:1660 E:1663 ||| CD
U  ||| S:1663 E:1665 ||| NNP
[ ||| S:1665 E:1666 ||| -LRB-
11220 ||| S:1666 E:1671 ||| LS
] ||| S:1671 E:1672 ||| -RRB-
,  ||| S:1672 E:1674 ||| ,
p    ||| S:1674 E:1676 ||| CD
< ||| S:1676 E:1677 ||| SYM
0.01 ||| S:1678 E:1682 ||| CD
) ||| S:1682 E:1683 ||| -RRB-
.  ||| S:1683 E:1685 ||| .
FFR  ||| S:1685 E:1689 ||| SYM
and  ||| S:1689 E:1693 ||| CC
IMR  ||| S:1693 E:1697 ||| NNP
measurements  ||| S:1697 E:1710 ||| NNS
differ  ||| S:1710 E:1717 ||| VBP
between  ||| S:1717 E:1725 ||| IN
CKD  ||| S:1725 E:1729 ||| NNP
patients  ||| S:1729 E:1738 ||| NNS
and  ||| S:1738 E:1742 ||| CC
those  ||| S:1742 E:1748 ||| DT
with  ||| S:1748 E:1753 ||| IN
normal  ||| S:1753 E:1760 ||| JJ
renal  ||| S:1760 E:1766 ||| JJ
function ||| S:1766 E:1774 ||| NN
.  ||| S:1774 E:1776 ||| .
Flow-limiting  ||| S:1776 E:1790 ||| NNP
FFR  ||| S:1790 E:1794 ||| NNP
is  ||| S:1794 E:1797 ||| VBZ
less  ||| S:1797 E:1802 ||| RBR
frequent  ||| S:1802 E:1811 ||| JJ
in  ||| S:1811 E:1814 ||| IN
patients  ||| S:1814 E:1823 ||| NNS
with  ||| S:1823 E:1828 ||| IN
CrCl  ||| S:1828 E:1833 ||| JJ
≤45  ||| S:1833 E:1837 ||| CD
ml ||| S:1837 E:1839 ||| CD
/ ||| S:1839 E:1840 ||| CD
min.  ||| S:1840 E:1845 ||| CD
©  ||| S:1845 E:1847 ||| CD
2015  ||| S:1847 E:1852 ||| CD
Wiley  ||| S:1852 E:1858 ||| NNP
Periodicals ||| S:1858 E:1869 ||| NNP
,  ||| S:1869 E:1871 ||| ,
Inc ||| S:1871 E:1874 ||| NNP
.  ||| S:1874 E:1876 ||| .
